These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21694929)

  • 41. [Etiology, diagnostics and therapy of hyponatremias].
    Laczi F
    Orv Hetil; 2008 Jul; 149(29):1347-54. PubMed ID: 18617466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyponatremia in hospitalized patients: the potential role of tolvaptan.
    Deitelzweig SB; McCormick L
    Hosp Pract (1995); 2011 Aug; 39(3):87-98. PubMed ID: 21881396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypertonic saline, isotonic saline, water restriction, long loops diuretics, urea or vaptans to treat hyponatremia.
    Decaux G; Gankam Kengne F
    Expert Rev Endocrinol Metab; 2020 May; 15(3):195-214. PubMed ID: 32401559
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New agents for managing hyponatremia in hospitalized patients.
    Munger MA
    Am J Health Syst Pharm; 2007 Feb; 64(3):253-65. PubMed ID: 17244874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolvaptan, hyponatremia, and heart failure.
    Zmily HD; Daifallah S; Ghali JK
    Int J Nephrol Renovasc Dis; 2011; 4():57-71. PubMed ID: 21694950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebral correlates of hyponatremia.
    Nathan BR
    Neurocrit Care; 2007; 6(1):72-8. PubMed ID: 17356196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyponatremia in patients with heart failure.
    Filippatos TD; Elisaf MS
    World J Cardiol; 2013 Sep; 5(9):317-28. PubMed ID: 24109495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of Hyponatremia in Heart Failure: Practical Considerations.
    Şorodoc V; Asaftei A; Puha G; Ceasovschih A; Lionte C; Sîrbu O; Bologa C; Haliga RE; Constantin M; Coman AE; Petriș OR; Stoica A; Şorodoc L
    J Pers Med; 2023 Jan; 13(1):. PubMed ID: 36675801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.
    Praharaj DL; Anand AC
    J Clin Exp Hepatol; 2022; 12(2):575-594. PubMed ID: 35535075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions.
    Bhatt PR; McNeely EB; Lin TE; Adams KF; Patterson JH
    J Clin Med; 2014 Nov; 3(4):1276-90. PubMed ID: 26237603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
    Urso C; Brucculeri S; Caimi G
    J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India.
    Patra S; Kumar B; Harlalka KK; Jain A; Bhanuprakash HM; Sadananda KS; Basappa H; Santhosh K; Rajith KS; Bharathi KS; Manjunath CN
    Heart Views; 2014 Jan; 15(1):1-5. PubMed ID: 24949180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
    Orlandi C; Zimmer CA; Gheorghiade M
    Future Cardiol; 2006 Nov; 2(6):627-34. PubMed ID: 19804253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of hyponatremia: role of vaptans].
    Hensen J
    Internist (Berl); 2010 Dec; 51(12):1499-509. PubMed ID: 21104220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.